立体定向放射治疗前列腺癌

IF 1.4 4区医学 Q4 ONCOLOGY

Cancer Radiotherapie Pub Date : 2025-08-20 DOI:10.1016/j.canrad.2025.104709

Ulrike Schick , Delphine Antoni , Stéphanie Josset , Thomas Lacornerie , Jocelyne Mazurier , Laure Parent , David Pasquier

{"title":"立体定向放射治疗前列腺癌","authors":"Ulrike Schick , Delphine Antoni , Stéphanie Josset , Thomas Lacornerie , Jocelyne Mazurier , Laure Parent , David Pasquier","doi":"10.1016/j.canrad.2025.104709","DOIUrl":null,"url":null,"abstract":"<div><div>Stereotactic body radiotherapy, also referred to as extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Since its introduction in the early 2000s, several single-centre and two multi-institutional randomized trials have evaluated stereotactic body radiotherapy for prostate cancer, typically reporting median follow-ups of 5 to 10 years. Given favourable outcomes, stereotactic body radiotherapy has now become a standard of care for intermediate prostate cancer. The aim of this review is to report the current evidence so far, and to assess specificities of this irradiation modality. Extreme fractionation in case of pelvic irradiation or intraprostatic relapse will not be addressed in this review.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 5","pages":"Article 104709"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stereotactic radiotherapy for prostate cancer\",\"authors\":\"Ulrike Schick , Delphine Antoni , Stéphanie Josset , Thomas Lacornerie , Jocelyne Mazurier , Laure Parent , David Pasquier\",\"doi\":\"10.1016/j.canrad.2025.104709\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Stereotactic body radiotherapy, also referred to as extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Since its introduction in the early 2000s, several single-centre and two multi-institutional randomized trials have evaluated stereotactic body radiotherapy for prostate cancer, typically reporting median follow-ups of 5 to 10 years. Given favourable outcomes, stereotactic body radiotherapy has now become a standard of care for intermediate prostate cancer. The aim of this review is to report the current evidence so far, and to assess specificities of this irradiation modality. Extreme fractionation in case of pelvic irradiation or intraprostatic relapse will not be addressed in this review.</div></div>\",\"PeriodicalId\":9504,\"journal\":{\"name\":\"Cancer Radiotherapie\",\"volume\":\"29 5\",\"pages\":\"Article 104709\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Radiotherapie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1278321825001258\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Radiotherapie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1278321825001258","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

立体定向全身放射治疗，也被称为极端低分割，使用先进的输送技术，每个部分给予高剂量的辐射。自21世纪初引入立体定向放疗以来，几项单中心和两项多机构随机试验评估了立体定向放疗治疗前列腺癌的效果，通常报告中位随访期为5至10年。鉴于良好的结果，立体定向放射治疗现已成为中度前列腺癌的标准治疗方法。本综述的目的是报告目前的证据，并评估这种照射方式的特异性。在骨盆照射或前列腺内复发的情况下，极端分离将不会在本综述中讨论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Stereotactic radiotherapy for prostate cancer

Stereotactic body radiotherapy, also referred to as extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Since its introduction in the early 2000s, several single-centre and two multi-institutional randomized trials have evaluated stereotactic body radiotherapy for prostate cancer, typically reporting median follow-ups of 5 to 10 years. Given favourable outcomes, stereotactic body radiotherapy has now become a standard of care for intermediate prostate cancer. The aim of this review is to report the current evidence so far, and to assess specificities of this irradiation modality. Extreme fractionation in case of pelvic irradiation or intraprostatic relapse will not be addressed in this review.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Radiotherapie 医学-核医学

CiteScore

2.20

自引率

23.10%

发文量

129

审稿时长

63 days

期刊介绍： Cancer/radiothérapie se veut d''abord et avant tout un organe francophone de publication des travaux de recherche en radiothérapie. La revue a pour objectif de diffuser les informations majeures sur les travaux de recherche en cancérologie et tout ce qui touche de près ou de loin au traitement du cancer par les radiations : technologie, radiophysique, radiobiologie et radiothérapie clinique.